Recombinant Influenza vaccine is more effective than standard inactivated vaccine

News Hour:

Although the development of the inactivated influenza vaccine (IIV) was a major public health achievement, the current vaccine has clear limitations: effectiveness varies from year to year, and egg protein is troublesome for some. Investigators conducted an industry-supported multicenter comparison of safety and efficacy of two vaccines during the 2014-2015 season.

They compared a new, quadrivalent influenza vaccine (RIV4) containing 45 μg each of four recombinant influenza hemagglutinin (HA) proteins produced in serum-free medium with an FDA-approved IIV containing 15 μg each of the same four HA proteins. The study population enrolled was 9003 patients aged 50 or older who were not acutely ill or receiving immunosuppressive therapy.

The incidence of confirmed influenza illness was 30% lower in the RIV4 recipients (2.2%) than in the IIV recipients (3.2%). The higher efficacy was solely against influenza A (36%) as opposed to influenza B (none) and endured throughout the influenza season. There were no notable differences in adverse events between the two study groups.

News Hour Correspondent

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Why Japan took a long time to go for country lockdown?
Honor Blackman, James Bond actress dies at 94
Ukraine battles forest fire in Chernobyl nuclear zone
Lady Gaga announces star-studded coronavirus benefit telecast
New Zealand demotes minister for coronavirus lockdown breach, extends emergency
Two South Koreans recover from coronavirus after plasma therapy


News of the Month

Scroll Up
%d bloggers like this: